MED12 and non-small cell lung carcinoma: Based on this finding, to establish a clinically applicable treatment strategy for RTKi-resistant NSCLC induced by MED12 mutations, we tested whether the MEK inhibitor trametinib could be effective as a single agent in NSCLC with MED12 mutations resistant to RTK inhibitors.